Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05050201
Other study ID # GN21MH015
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 20, 2021
Est. completion date September 30, 2022

Study information

Verified date September 2021
Source NHS Greater Glasgow and Clyde
Contact Elaine O'Neill - Senior Research Administrator
Phone 0141 314 4011
Email Elaine.O'Neill2@ggc.scot.nhs.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study uses mixed methods to investigate the implementation of digital cognitive behavioural therapy for insomnia (Sleepio) in a first episode of psychosis service (FEP). Interviews will be conducted with keyworker clinicians and service users to consider their expectations for digital sleep intervention. The rates of recruitment into the study, eligibility, completion of baseline measures, completion of the intervention sessions, attrition from the intervention and completion of follow up measures will be recorded. Interviews will be conducted with keyworker clinicians and service users to consider their experiences of digital sleep intervention. The primary outcome will be a logic model describing factors acting upon the implementation of Sleepio in this population. The investigators will provide signal data in relation to changes in insomnia severity, psychosis symptomatology, and general mental health.


Description:

First episode psychosis (FEP) services present a unique opportunity to effect change in outcomes in those affected by experiences of psychosis. Sleep disorder, particularly insomnia, is common in those affected by psychosis, including those experiencing a first episode and are associated with increased symptomatology. Mood and worry mediate the relationship between sleep and psychosis symptomatology and research suggests that improving sleep in this population can improve mental health symptomatology and longer term outcomes. Cognitive Behavioural Therapy is effective in treating insomnia (CBT-I). Pilot research suggests that insomnia is a tractable clinical target in psychosis. Furthermore, there is an appetite for therapeutic interventions for sleep in this population. "Sleepio" is an online Cognitive Behavioural Therapy for Insomnia (CBT-I) programme. Sleepio's components are those common to CBT-I interventions: i) Psychoeducation on sleep hygiene and processes; ii) cognitive components including restructuring, mindfulness, positive imagery, paradoxical intention training (trying to stay awake), and resolving thoughts about one's day; and iii) behavioural components including sleep restriction, stimulus control, and relaxation techniques. Sleepio is composed of six 20-minute sessions presented by an animated therapist ("the Professor"), which are unlocked weekly. Participants complete an initial assessment (please see 'Sleepio Onboarding Questions') and chose a treatment goal, which drives initial personalisation of the application. Participants book digital 'appointments' with the Professor and receive prompts to complete these 6 sessions, to enter sleep data and to complete the Sleep Condition Indicator. The Sleepio algorithm tailors ongoing intervention based on this sleep data and other data about participants' physical and mental health. Sleepio also provides access to online psychoeducation and a clinician-moderated user forum. This intervention has been shown to be as effective as 1-1 CBT-I in the general population. Sleepio has been used in mental health populations but has not yet been tested in people experiencing a first episode of psychosis. The study aims to use mixed methods to determine how digital CBT-I can be implemented in first episode psychosis services. These data will be integrated to build a logic model, based on the Medical Research Council (MRC) complex interventions framework. Keyworkers in Esteem FEP services will be approached to identify service users affected by sleep difficulties that may benefit from Sleepio. Service user participants will be recruited through their treatment as usual (TAU) with their Esteem keyworker (sleep monitoring is part of this). Where service users report sleep difficulties, keyworkers will offer an information leaflet about the study and referral into the research study or contact details for researchers (study email address). Keyworkers will record that service users have agreed to keyworkers providing their details to researchers and to being contacted by the researchers in their casefile. Those service users who wish to find out more about the study and meet eligibility criteria will be sent an easy-read Participant Information Sheet and Consent Form. They will be given the opportunity to ask questions and will be encouraged to speak to others about their potential participation (such as their keyworker). It will be made clear that in consenting to participate they are consenting to participate in sleep assessment, complete symptomatology measures pre- and post-intervention and use the Sleepio intervention. It will be made clear that participation does not affect their TAU. They will provide written consent if they wish to participate. Consenting service user study participants will receive access to Sleepio. They will register for the intervention with a researcher during the baseline symptomology measures assessment session. They will be given the option of additionally participating in semi-structured interviews prior to and after using the intervention, to talk about their expectations and experiences of Sleepio. Service user participants will not be randomized to treatment. All service user participants will be provided with access to Sleepio. Research will focus on developing a model for the implementation of this intervention. Keyworkers will be introduced to and supported in their role in referring service users to the study and monitoring use of Sleepio through presentations, psychosocial supervision, and reflection sessions. Keyworkers will be provided with an easy read information sheet which clarifies their role as clinicians (attending a session to reflect on their caseload and service user suitability for the study and providing suitable service users with information about the study) and potentially as research participants (in semi-structured interviews) via email and letter. They will be given the opportunity to ask questions and will be encouraged to speak to others about their potential interview participation (such as their colleagues). They will provide written consent if they wish to participate in semi-structured interviews, to talk about their expectations and experiences of Sleepio use in Esteem. Primary outcomes comprise implementation data and qualitative data concerning the perspectives of clinicians and service users, which inform the resulting logic model. Secondary outcome data comprises insomnia severity (Insomnia Severity Index), mental health symptomatology (Depression Anxiety and Stress Scales; The Revised Green et al., Paranoid Thoughts Scale (R-GPTS); Specific Psychotic Experiences Questionnaire (SPEQ) - Hallucinations Subscale) and worry about Covid19 (Fear of Covid19 Scale).


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date September 30, 2022
Est. primary completion date April 20, 2022
Accepts healthy volunteers No
Gender All
Age group 16 Years to 35 Years
Eligibility Inclusion Criteria: - Service users under the care of Esteem First Episode Psychosis Service in NHS GGC - Potentially affected by Insomnia Disorder (defined by Sleep Condition Indicator-02 score =2) - Who have access to a device they can use Sleepio on (a computer device with Safari or Google Chrome browser, or an iPhone device). Exclusion Criteria: - Moderate to severe learning disability - Acute Psychosis (recent crisis contact or hospitalisation) - Incapacity to provide informed consent - Insufficient English to access intervention - Organic impairment - No access to a device which can be used for Sleepio intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sleepio
Digital CBT application for insomnia

Locations

Country Name City State
United Kingdom Esteem North, NHS Greater Glasgow and Clyde Glasgow
United Kingdom Esteem South and Clyde, NHS Greater Glasgow and Clyde Glasgow

Sponsors (3)

Lead Sponsor Collaborator
NHS Greater Glasgow and Clyde Big Health, University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Implementation data - rates of consenting Rates of consenting and nonconsenting interested participants Across study timeline (8 months), across 10 weeks for Sleepio specific measures
Primary Implementation data - eligibility Number of eligible vs. ineligible participants and reasons for ineligibility 8 months
Primary Implementation data - completion of measures Participant completion of measures assessment appointments and measures (ISI measure of insomnia severity, DASS-21 measure of mental wellbeing, R-GPTS measure of paranoia, SPEQ measure of hallucination, and Fear of Covid19). This outcome records whether or not these were completed by participants, whereas secondary outcomes 6-10 examine participant scores on these measures. 8 months
Primary Implementation data - completion of intervention sessions Measures attrition from intervention by recording how many sessions of intervention were completed by participant. Across 10 weeks per participant
Primary Qualitative data Service user and clinician expectations and experiences of digital CBT-I intervention Across study timeline (8 months), across 12 weeks for service users (pre and post intervention)
Secondary Insomnia severity As measured by the Insomnia Severity Index (ISI). Possible scores range from 0 to 28 and higher scores indicate more severe insomnia. 10 weeks
Secondary Mental Wellbeing As measured by the Depression, Anxiety and Stress Scales (DASS-21). Possible scores range from 0 to 126 and higher scores indicate more psychological distress. The maximum score on each subscale (depression, anxiety, stress) is 42. 10 weeks
Secondary Paranoia symptomatology As measured by the Revised Green et al., Paranoid Thoughts Scale (R-GPTS). Possible scores range from 0 to 72 and higher scores indicate more severe paranoia. 10 weeks
Secondary Hallucination symptomatology As measured by the Specific Psychotic Experiences Questionnaire (SPEQ) - Hallucinations subscale. Possible scores range from 0 to 45 and higher scores indicate more severe hallucinatory experience. 10 weeks
Secondary Anxiety regarding Covid19 As measured by the Fear of Covid19 Scale. Possible scores range from 7 to 35 and higher scores indicate more fear of Covid19. 10 weeks
See also
  Status Clinical Trial Phase
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Completed NCT06339853 - Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia N/A
Recruiting NCT04069247 - Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia N/A
Completed NCT04493593 - Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Recruiting NCT06278077 - Neurexan - a Clinical Trial in Short-Term Insomnia Patients Phase 2
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Recruiting NCT06207279 - Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
Recruiting NCT06006299 - Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04035200 - Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2
Active, not recruiting NCT05027438 - Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Not yet recruiting NCT06348082 - Project Women's Insomnia Sleep Health Equity Study (WISHES) N/A
Not yet recruiting NCT06363799 - Osteopathic Protocol for Insomnia in College Students N/A
Not yet recruiting NCT05991492 - Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application N/A
Not yet recruiting NCT06025968 - Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis N/A